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Type 1 plasminogen activator inhibitor (PAI-1), the
primary inhibitor of tissue-type plasminogen activator
(t-PA), circulates as a complex with the abundant
plasma glycoprotein, vitronectin. This interaction stabi-
lizes the inhibitor in its active conformation In this re-
port, the effects of vitronectin on the interactions of
PAI-1 with fibrin clots were studied. Confocal micro-
scopic imaging of platelet-poor plasma clots reveals that
essentially all fibrin-associated PAI-1 colocalizes with
fibrin-bound vitronectin. Moreover, formation of plate-
let-poor plasma clots in the presence of polyclonal anti-
bodies specific for vitronectin attenuated the inhibitory
effects of PAI-1 on t-PA-mediated fibrinolysis. Addition
of vitronectin during clot formation markedly potenti-
ates PAI-1-mediated inhibition of lysis of 125I-labeled
fibrin clots by t-PA. This effect is dependent on direct
binding interactions of vitronectin with fibrin. There is
no significant effect of fibrin-associated vitronectin on
fibrinolysis in the absence of PAI-1. The binding of PAI-1
to fibrin clots formed in the absence of vitronectin was
characterized by a low affinity (Kd ; 3.5 mM) and rapid
loss of PAI-1 inhibitory activity over time. In contrast, a
high affinity and stabilization of PAI-1 activity charac-
terized the cooperative binding of PAI-1 to fibrin formed
in the presence of vitronectin. These findings indicate
that plasma PAI-1zvitronectin complexes can be local-
ized to the surface of fibrin clots; by this localization,
they may modulate fibrinolysis and clot reorganization.
Tissue-type plasminogen activator (t-PA)1 initiates intravas-
cular fibrinolysis by binding to fibrin, where it activates fibrin-
bound plasminogen (1–4). The major inhibitor of t-PA, type 1
plasminogen activator inhibitor (PAI-1), circulates in plasma
and is released from platelet a-granules during blood clotting
(5, 6). PAI-1 accumulates in thrombi, rendering them resistant
to t-PA-mediated fibrinolysis (7–14). In purified systems, PAI-1
has been shown to bind directly to fibrin, with a Kd of 3.7 mM
(15–18). Consequently, it has been hypothesized that PAI-1
accumulation in thrombi reflects a direct interaction of PAI-1
with fibrin.
PAI-1 circulates in plasma (19, 20) and platelets in complex
with vitronectin (21, 22, 23, 24), a glycoprotein that binds PAI-1
with high affinity (25). The vitronectin interaction with PAI-1
stabilizes the inhibitor in its active conformation (26, 27), in-
duces allosteric changes in vitronectin that expose cryptic
epitopes (28, 29), and modulates vitronectin-dependent cell
adhesion (25, 30, 31). Domain mapping studies using proteol-
ysis, synthetic peptides, monoclonal antibodies, and site-di-
rected mutagenesis have identified two discrete sites on
vitronectin that may bind and stabilize PAI-1 (27, 33, 34).
Similar approaches have delineated a single vitronectin-bind-
ing site on PAI-1 (35, 36).
Recent studies from our laboratories have further character-
ized the PAI-1-vitronectin interaction. Analytical ultracentrif-
ugation experiments indicate that PAI-1 and native vitronectin
form a 320-kDa complex composed of two vitronectin and four
PAI-1 molecules, suggesting a 2:1 stoichiometry.2 Binding
studies using domain-specific monoclonal antibodies support
the concept that there are two PAI-1-binding sites on vitronec-
tin. The reported Mr of circulating PAI-1zvitronectin complexes
(19, 20) is consistent with our results and raises the possibility
that the complex, rather than the individual proteins, interacts
with other macromolecules. Supporting this concept are stud-
ies demonstrating that vitronectin can bind PAI-1 and heparin
simultaneously, indicating that PAI-1zvitronectin complexes
can interact with other molecules (37).
Immunolocalization studies demonstrating both PAI-1 and
vitronectin on fibrils of fibrin clots formed in vitro or in vivo (38,
39) are compatible with the notion that the individual proteins
interact with fibrin. Although PAI-1 has been reported to bind
directly to fibrin, it has yet to be shown that vitronectin or
PAI-1zvitronectin complexes interact directly with fibrin. Re-
cently, we demonstrated that vitronectin associates with fibrin
in both purified and plasma systems.3 Based on these observa-
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tions, we hypothesized that fibrin-bound vitronectin supports
PAI-1 binding. To explore this possibility, direct binding stud-
ies were performed to quantify the interaction between PAI-1
and fibrin-bound vitronectin. In addition, functional PAI-1 as-
says were used to demonstrate that vitronectin enhances the
inhibitory effects of PAI-1 on t-PA-mediated clot lysis.
EXPERIMENTAL PROCEDURES
Chemicals, Proteins, Reagents—Human glu-plasminogen, a-throm-
bin, fibronectin, and plasminogen-free fibrinogen was purchased from
Enzyme Research Laboratories Inc. (South Bend, IN). Predominantly
single-chain recombinant t-PA (Activase®) was obtained from Genen-
tech Inc. (San Francisco, CA). The plasmin-directed chromogenic sub-
strate S2251 was obtained from Chromogenix (Mölndal, Sweden). High
binding 96-well microtiter plates were obtained from Costar Science
Corp. (Cambridge, MA). Bovine serum albumin (Fraction V), p-nitro-
phenyl phosphate, alkaline phosphatase-conjugated streptavidin, soy-
bean trypsin inhibitor, and phenylmethylsulfonyl fluoride were pur-
chased from Life Technologies, Inc. Reduced glutathione, Tween-80,
ethanolamine, diethanolamine, caprylic acid, and mouse IgG were ob-
tained from Sigma. Affinity-purified sheep anti-human vitronectin IgG
(SAHVn) and normal (nonimmune) sheep IgG were obtained from Af-
finity Biologicals (Hamilton, Ontario, Canada). Monoclonal antibody to
PAI-1 (MAI-12) was purchased from Biopool AB (Umeä, Sweden). Plas-
tic inoculation loops were obtained from Fisher Scientific (Nepean,
Ontario, Canada). Tween-20, Coomassie Brilliant Blue R-250, urea
(electrophoresis grade), acrylamide:bis 37.5:1 (2.6%C), molecular
weight markers, glycine, TRIS, SDS, G-25M Sepharose, and gelatin
were purchased from Bio-Rad. Specta/Por® CE (cellulose ester) MWCO
15,000 dialysis membrane tubing was purchased from VWR-Canlab
(Mississauga, Ontario, Canada).
Preparation of Platelet-poor Plasma (PPP)—Blood was collected from
the antecubital vein of healthy volunteers into plastic syringes prefilled
with 1⁄10 vol of 3.8% trisodium citrate. After mixing, the red blood cells
and platelets were sedimented by centrifugation at 1800 3 g for 15 min
at 4 °C, and PPP was harvested and stored at 270 °C until needed.
Isolation of Vitronectin and Fibrinogen from Human Plasma—Na-
tive vitronectin was purified and characterized as described previously
(23). Briefly, vitronectin was isolated from PPP using immunoaffinity
purification with the SAHVn IgG coupled to Affi-Gel affinity resin
(Bio-Rad) and subjected to PAGE analysis in the presence or absence of
SDS. Fibrinogen was rendered vitronectin-free using immunoaffinity
chromatography with immobilized SAHVn IgG, which reduced the
vitronectin levels from approximately 10 nM down to ,10 pM vitronectin
per mM fibrinogen.
Preparation of Radiolabeled Fibrinogen and PAI-1—Fibrinogen was
trace radiolabeled with Na125I using Iodobeads (Pierce) to a specific
activity of ;100 mCi/mg, and its clotting activity was assessed by
measuring its incorporation into fibrin clots (95–98%) (42). Recombi-
nant human PAI-1 containing the 6 residual peptide consensus se-
quence for heart muscle kinase (HMK) at the amino terminus was
constructed using the polymerase chain reaction, and the resulting
fusion protein was expressed in Escherichia coli and isolated as de-
scribed (43). When HMK-rPAI-1 was compared with fully active wild-
type rPAI-1, both proteins inhibited t-PA and urokinase-type PA to the
same extent, and both bound to vitronectin comparably. HMK-PAI-1
was radiolabeled by incubation with [32P]ATP (ICN Radiochemicals,
Oakville, Ontario, Canada) in the presence of purified protein kinase
from bovine heart muscle (Sigma), and the labeled protein was isolated
by gel filtration on G-25M Sepharose. The specific activity of the 32P-
PAI-1 was approximately 5800 cpm/ng.
Immunocytochemistry and Image Analysis—To examine the spatial
distribution of PAI-1 and vitronectin in clots, 150 ml of PPP was placed
on APTEX-coated coverslips and clotted by the addition of CaCl2 (final
concentration, 10 mM). After incubation at 37 °C for 1 h, the clots were
fixed with cold 3% formaldehyde in PBS for 5 min, washed alternately
with PBS alone and PBS containing 0.1 mol/liter glycine, and then
incubated for 30 min with blocking buffer (PBS containing 0.5% bovine
serum albumin and 50 mg/ml normal goat immunoglobulin). Primary
antibodies, including a monoclonal anti-PAI-1 IgG (monoclonal anti-
body MAI-12), SAHVn IgG, and a sheep anti-human fibrinogen IgG
were diluted in blocking buffer and incubated with the clots for 1 h at
37 °C. Control clots were stained with each primary antibody sepa-
rately, stained without primary antibodies, or stained with nonspecific
mouse and sheep IgG. After washing, clots were incubated for 1 h at
37 °C with Texas Red rhodamine-conjugated goat anti-sheep or fluores-
cein isothiocyanate-conjugated goat anti-mouse IgG diluted 1:20 in
blocking buffer. The coverslips were washed, mounted on glass slides
using Permafluor mounting medium, and then subjected to Z-plane
optical sectioning (200 nm/section) using a Zeiss LSM 10 equipped with
a 633 planapo oil immersion lens (numerical aperture 5 1.4). Dual-
wave-length images were acquired using an argon ion laser (488 nm
excitation), a helium/neon ion laser (543 nm excitation), and two
matched long pass barrier filters for fluorescein isothiocyanate (515–
525 nm emission) and Texas Red rhodamine (575–640 nm emission)
images. Image processing and three-dimensional volume rendering
were performed using Metamorph software (Universal Imaging Inc.,
Chester, PA). Clots stained with nonspecific primary antibodies were
used to threshold for background staining.
Lysis of 125I-Fibrinogen-labeled Plasma and Purified Fibrin Clots—
125I-Labeled clots were formed around plastic inoculation loops (44) by
clotting 250-ml aliquots of PPP or a solution containing purified fibrin-
ogen and glu-plasminogen (final concentrations, 3 and 0.54 mM, respec-
tively) diluted in Tris-buffered saline (TBS) (0.05 M Tris, pH 7.4, con-
taining 0.15 M NaCl, 0.025% Tween 80, 5 nM thrombin, and 25 mM
CaCl2). Prior to clotting, these solutions were spiked with
125I-fibrino-
gen (500,000 cpm/ml). The purified clots were also formed in the pres-
ence of various concentrations of PAI-1 and/or vitronectin. All clots were
allowed to age for 2 h at 37 °C. After repeated washing with TBS, clots
were then incubated with 0.1 nM t-PA or TBS at 37 °C. The extent of
t-PA-induced clot lysis was quantified by counting the radioactivity of
the residual clots. In addition, aliquots of the bathing buffer were
removed at intervals to monitor the time course of the release of 125I-
labeled fibrin degradation product. For some experiments, plasma clots
were formed in the presence or absence of antibodies directed against
PAI-1 (MAI-12) or vitronectin (SAHVn). Treatment of the clots with
MAI-12 or SAHVn attenuated PAI-1-mediated inhibition of clot lysis in
a dose-dependent manner, with maximal inhibition at 10 and 250
mg/ml, respectively. Previous reports have demonstrated that the mono-
clonal MAI-12 attenuates PAI-1-mediated inhibition of t-PA-dependent
clot lysis (11, 16). The SAHVn IgG attenuates the binding of PAI-1 to
vitronectin immobilized on the surface of microtiter wells in a dose-de-
pendent fashion.
The percentage of clot lysis was calculated by subtracting the resid-
ual radioactivity of the clots from their initial radioactivity, and ex-
pressed this value as a percentage of the initial radioactivity. The
vitronectin-dependent inhibition of t-PA-mediated lysis of purified clots
was confirmed by solubilizing the residual clots formed in the presence
or absence of PAI-1 and/or vitronectin with 13 Laemmli sample buffer
in the presence or absence of 5% 2-mercaptoethanol and boiled for 1 h
(45). The undissolved portion of the clot was pelleted by centrifugation,
50% of each of the dissolved clots and preclot supernatant samples were
subjected to SDS-PAGE (7.5% polyacrylamide gel), and the gels were
fixed and stained with Coomassie Blue. The dried gels then exposed to
autoradiography film to visualize the distribution of fibrin and fibrin
fragments (46).
Effects of Vitronectin and PAI-1 on t-PA-mediated Plasmin Genera-
tion on Fibrin Matrices—To examine the effects of vitronectin on PAI-1
inhibition of t-PA-dependent plasmin generation on fibrin matrices,
microtiter wells were first coated with fibrin formed by clotting 50-ml
aliquots of a fibrinogen (375 nM) solution containing 0.5 nM vitronectin
(or buffer alone) with 30 nM thrombin, 20 nM CaCl2. After incubation for
3 h at room temperature, the plates were stored at 4 °C until used.
Previous studies have determined that the addition of 0.5 nM vitronec-
tin to 375 nM fibrinogen prior to clotting resulted in the highest ratio of
fibrin-bound versus free vitronectin.3 To block nonspecific binding,
100-ml aliquots of PBS containing 3% bovine serum albumin and 0.05%
Tween-20 (blocking buffer) were added to wells for 2 h at 37 °C. The
fibrin-coated wells were then preincubated for 1 h at 37 °C with increas-
ing concentrations of PAI-1 (0.01–100 nM) diluted in PBS containing 3%
bovine serum albumin, 0.1% Tween-80, 5 mM EDTA, 20 units/ml apro-
tinin, and 0.05% sodium azide (dilution buffer). For some experiments,
fibrin matrices were incubated with PAI-1 in the presence or absence of
10 mg/ml of SAHVn IgG or preimmune sheep IgG. After washing three
times with TBS containing 0.1% bovine serum albumin and 0.05%
Tween-20 (wash buffer), the wells were then incubated at 37 °C for
intervals of up to 24 h. At each time point, 0.48 nM t-PA, 0.54 mM
glu-plasminogen, and 1 mM S-2251 were added, and the rate of plasmin
generation was quantified by measuring the absorbance at 405 nm
(A405 nm) every min for 1 h. Rates of plasmin generation were expressed
as a percentage of the maximum rate of plasmin generation in which no
PAI-1 was added. Using the residual plasmin activity at each concen-
tration of PAI-1, we calculated the amount of PAI-1 that bound to fibrin
in the presence and absence of vitronectin, and the apparent Kd (Kd(app))
was calculated for each condition using regression analysis.
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Binding of 32P-HMK-PAI-1 to Fibrin Clots Formed in the Presence or
Absence of Vitronectin—The binding of radiolabeled PAI-1 to fibrin-
coated (375 nM) microtiter plate wells was quantified in the presence or
absence of 0.5 nM vitronectin. Various concentrations of 32P-HMK-
PAI-1 (0.01–22 nM) in dilution buffer were incubated for 1 h at 37 °C
with the fibrin matrices that were formed in the presence or absence of
vitronectin. After the wells were rinsed three times with wash buffer,
the bound and free PAI-1 were quantified by scintillation counting.
Data for vitronectin-dependent binding of PAI-1 to fibrin (B in Equation
1) were analyzed by nonlinear least squares analysis according to the
Hill equation,
B 5 ~Bmax z @S#n!/~~K0.5!n 1 @S#n! (Eq. 1)
in which S is the total PAI-1 concentration, Bmax is the amount of PAI-1
bound at saturation, K0.5 corresponds to the PAI-1 concentration at
half-maximal saturation, and n is the Hill coefficient.
RESULTS
Microscopic Colocalization of Plasma Clot-associated PAI-1
and Vitronectin—Although previous immunohistochemistry
studies have demonstrated that PAI-1 and vitronectin are each
localized on fibrin (38, 39), the extent to which these proteins
colocalize has yet to be determined. Recently, we described the
ultrastructural distribution of vitronectin aggregates associ-
ated with the surface of fibrin fibrils formed by clotting plasma
or purified fibrinogen.3 To determine whether fibrin-associated
vitronectin regulates PAI-1 distribution in clots, plasma clots
were processed for dual-labeling immunofluorescence and con-
focal scanning laser microscopic image analysis to examine the
distribution of plasma vitronectin and PAI-1 on fibrin fibrils
(Fig. 1). Digitalized thresholding of optical sections from clots
stained in the absence of a primary antibody or with preim-
mune IgG was used to establish the background levels of fluo-
rescence. Fibrin-associated vitronectin staining is intense, and
is distributed in a punctate, aggregate-like pattern along the
fibrin fibrils (Fig. 1A). Specific PAI-1 staining is distributed
intermittently along the length of the fibrin fibrils, with in-
tense staining noted at junctions of overlapping fibrin fibrils
(Fig. 1B, arrows). Quantitative analysis of the percentage of
staining for PAI-1 that overlaps with that for vitronectin re-
veals that the majority (.87%) of fibrin-bound PAI-1 (Fig. 1C,
green) colocalizes with the vitronectin aggregates (red) on the
surface of fibrin fibrils (Fig. 1C, yellow). To define the distribu-
tion of fibrin fibrils, plasma clots also were stained for fibrin
(Fig. 1D).
Influence of Vitronectin on PAI-1-mediated Inhibition of Clot
Lysis—To examine the influence of fibrin-associated vitronec-
tin on PAI-1 activity, we monitored the t-PA-mediated lysis of
125I-fibrinogen-labeled plasma clots (Fig. 2). First, we quanti-
fied the t-PA dose- and time-dependent lysis profiles of 125I-
fibrinogen-labeled plasma clots in order to determine an opti-
mal t-PA concentration that results in approximately 40–50%
lysis after 18–24 h of incubation (Fig. 2A). Based on these
results, we used 0.08 nM t-PA to examine the lysis of plasma
FIG. 1. Confocal imaging of vitronectin and PAI-1 colocaliza-
tion in plasma clots. Pseudo-colored images of optical sections
through plasma clots stained with an affinity-purified anti-vitronectin
IgG (A) or a monoclonal anti-PAI-1 (B), and each primary was detected
with Texas Red rhodamine-conjugated and fluorescein isothiocyanate-
conjugated secondary antibodies, respectively. Digital overlap analysis
of the vitronectin (red) and PAI-1 (green) images (C) indicates that the
majority (.87%) of the PAI-1 distribution overlaps with the vitronectin
(yellow) on fibrin fibrils. Staining with anti-fibrinogen IgG (D) illus-
trates the distribution of fibrin polymers. To facilitate image compari-
sons, the arrows in A and B provide points of reference where PAI-1
staining is most intense at sites of fibrin fibril overlap. Scale bar, 10 mm.
FIG. 2. Neutralization of PAI-1-dependent inhibition of plasma
clot lysis by vitronectin antibodies. A, effects of varying the t-PA
concentration on the time-dependent lysis of clots formed using plasma
containing 100,000 cpm of 125I-fibrinogen. After clotting, samples were
washed with PBS and then incubated at 37 °C for various times in 1 ml
of PBS containing buffer alone (V) or different doses of t-PA: 0.02 nM
(f), 0.08 nM (Œ), 0.2 nM (), 0.4 nM (l), and 0.8 nM (3). At each time
point, clots and clot supernatants were then separated and counted.
Data are expressed as percentage of clot lysis and represent the mean
(n 5 3) 6 S.D. of one of five experiments. A, effects of antibodies directed
against PAI-1 and vitronectin (Vn) on the lysis of plasma clots. Clots
were formed using plasma containing 100,000 cpm of 125I-fibrinogen in
the absence (NO PAI-1) or presence of 1.0 mg/ml (22 nM) PAI-1 alone
(NO IgG) or PAI-1 plus anti-PAI-1 IgG (10 mg/ml) (ANTI-PAI-1), an-
ti-Vn IgG (250 mg/ml) (ANTI Vn), or equivalent concentrations of non-
immune mouse or nonimmune sheep IgG (NM/NS). After clotting,
samples were washed with PBS and then incubated at 37 °C for 18 h in
1 ml of PBS containing 0.08 nM t-PA. Clots and clot supernatants were
then separated and counted. Data are expressed as percentage of clot
lysis and represent the mean (n 5 3) 6 S.D. of one of five experiments.
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clots formed in the presence or absence of exogenous 1.0 mg/ml
PAI-1. As illustrated in Fig. 2B, approximately 37% of the
125I-fibrin-labeled plasma clots was digested in the absence of
exogenous PAI-1, whereas the addition of PAI-1 to the clot
significantly (p 5 0.001) reduced lysis to only 7%. Formation of
clots in the presence of antibodies against PAI-1 (MAI-12)
attenuated PAI-1-mediated inhibition of clot lysis, a finding
consistent with previous in vitro (11) and in vivo (16) studies
with this antibody. In contrast, the anti-vitronectin IgG
(SAHVn) completely blocked the inhibitory effects of PAI-1 on
clot lysis. Control experiments confirmed that the SAHVn IgG
did not contain any plasminogen activator activity, and this
antibody had no effect when added after clotting (data not
shown). Neither preimmune mouse nor sheep IgG had any
effect on clot lysis.
Fibrin-bound Vitronectin Potentiates the PAI-1-mediated In-
hibition of Fibrinolysis—To confirm the results with SAHVn
IgG in plasma, 125I-fibrinogen-labeled clots were formed from
3.0 mM purified fibrinogen, 22 nM PAI-1, 0.54 mM plasminogen,
and various doses of vitronectin. These clots were then exposed
to t-PA (Fig. 3). In control experiments, clots formed in the
presence of increasing concentrations of vitronectin, but in the
absence of PAI-1, no significant difference in t-PA-induced clot
lysis was demonstrated. Indeed, .95% of the fibrin was solu-
bilized (Fig. 3, open triangles). In the absence of vitronectin,
PAI-1 had only a modest inhibitory effect on clot lysis, with 85%
of the fibrin clot degraded (Fig. 3, open circle on left axis). When
PAI-1 was added in conjunction with increasing concentrations
of vitronectin there was a dose-dependent potentiation of PAI-
1-mediated inhibition of clot lysis (Fig. 3, closed circles), and
,10% of the clot was degraded with vitronectin doses .14 nM.
These results suggest that preformed PAI-1zvitronectin com-
plexes are incorporated into fibrin clots during coagulation. To
determine whether the potentiation of PAI-1-mediated inhibi-
tion of clot lysis is due to direct interactions of vitronectin with
fibrin, and to determine whether fibrin-bound vitronectin can
bind PAI-1, clots were first formed in the presence of increasing
doses of native vitronectin. After extensive washing, the clots
were then incubated with PAI-1 for 1 h prior to t-PA exposure
FIG. 3. PAI-1 inhibition of 125I-fibrin clot lysis is dependent on
vitronectin. Purified fibrin clots were formed using 3 mM fibrinogen
containing 100,000 cpm of 125I-fibrinogen per clot, 30 nM thrombin, 10
mM CaCl2, 0.54 mM glu-plasminogen, and increasing concentrations of
(i) vitronectin alone (‚), (ii) vitronectin plus 1.0 mg/ml (22 nM) PAI-1
(v), or (iii) vitronectin alone followed by 1.0 mg/ml PAI-1 in the bathing
buffer postclotting (V). Samples were clotted for 2 h at 37 °C, washed
and then incubated for 18 h at 37 °C in 1 ml of TBS buffer containing
0.08 nM t-PA. Clots and clot supernatants were then separated and
counted. Data are expressed as percentage of clot lysis and represents
the mean (n 5 3) 6 S.D. of one of five experiments.
FIG. 4. SDS-PAGE analysis of vitronectin and PAI-1 effects on fibrin degradation. Purified 125I-fibrinogen-labeled clots formed in the
presence or absence of vitronectin and/or PAI-1 and subjected to t-PA-mediated fibrinolysis were solubilized, and the extracts were fractionated
using SDS-PAGE under reduced and nonreduced conditions, followed by Coomassie Blue staining and autoradiography in order to visualize
changes in fibrin degradation. Numbers under the lanes correspond to the concentrations of vitronectin (Vn) and PAI-1 added together to the
fibrinogen mixture prior to clotting. Arrows: a, uncleaved fibrin polymers; b, fibrin fragments D, Y, and X; c, g-g dimers; d, b-chain fragments.
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(Fig. 3, open circles). These studies indicate that PAI-1 inhibi-
tion of clot lysis is less efficient when vitronectin is first pre-
bound to the fibrin clot during coagulation. Although these find-
ings may simply reflect impaired diffusion of PAI-1 into a
preformed clot, the results nonetheless demonstrate that fibrin-
bound vitronectin can still potentiate PAI-1-mediated inhibition
of t-PA. Furthermore, the results confirm that the incorpora-
tion of vitronectin into the clot is not PAI-1-dependent.
In order to confirm that purified vitronectin potentiates the
PAI-1-mediated inhibition of fibrinolysis, purified 125I-fibrino-
gen-labeled clots that had been subjected to t-PA-mediated
fibrinolysis were solubilized. The soluble extracts were frac-
tionated using SDS-PAGE under reduced and nonreduced con-
ditions in order to evaluate changes in fibrin degradation (Fig.
4). As demonstrated in Fig. 3, the presence of PAI-1 or vitronec-
tin alone had no significant effects on the degradation of fibrin
(Fig. 4). However, in the presence of PAI-1 and vitronectin
doses .4.0 mg/ml, the fibrin degradation pattern on nonre-
duced gels illustrates that vitronectin markedly inhibits the
degradation of fibrin polymers with a molecular mass of .250
kDa (Fig. 4, arrows a), and lower molecular mass forms of
covalently linked polymers of fragments D, Y, and X (arrows b).
The vitronectin-dependent potentiation of PAI-1-mediated
inhibition of fibrinolysis was further noted following reduc-
tion of the clot lysate samples as indicated by the increased
amounts of g-g dimers (Fig. 4, arrows c) and b-chain fragments
(arrows d).
Vitronectin Mediates the Binding and Stabilization of PAI-1
on Fibrin—To examine the effects of vitronectin on the binding
of active PAI-1 to fibrin, we used a functional assay as an index
of active PAI-1 bound to fibrin (Fig. 5). Fibrin clots formed in
the presence or absence of 0.5 nM vitronectin were incubated for
1 h with increasing concentrations of PAI-1. After washing, the
clots were then incubated for a further 1–24 h at 37 °C prior to
measuring the fibrin-bound PAI-1 activity using an amidolytic
substrate assay. From this information, the concentration of
functionally active PAI-1 bound to fibrin was estimated. Re-
gression analysis of the data was used to calculate Kd(app) for
the interaction between active PAI-1 and fibrin. In the absence
of vitronectin, very little active PAI-1 bound to fibrin after 1 h
of incubation, as the interaction is very weak (Kd(app) ; 3.5 mM).
Moreover, there was no fibrin-associated PAI-1 activity detect-
able after 24 h. In contrast, in the presence of vitronectin, the
Kd(app) values at 1 and 24 h were 0.7 and 0.9 nM, respectively.
These findings suggest that the fibrin-bound PAI-1 remains
functionally active over a 24-h period when in complex with
vitronectin. Furthermore, co-incubation of the PAI-1 dilutions
with 10 mg/ml of the SAHVn IgG increased the Kd(app) value up
to 60 nM after 24 h (data not shown), thereby confirming the
observed pro-fibrinolytic effect of this antibody in the lysis of
plasma clots (Fig. 2B).
We next directly quantified the specific binding of radiola-
beled PAI-1 to purified fibrin clots formed in the presence or
absence of vitronectin (Fig. 6). The results indicate that in the
absence of vitronectin (Fig. 6A, squares), there is only low
affinity binding of PAI-1 to fibrin, with an estimated micromo-
lar affinity similar to that calculated from the functional assays
in Fig. 5. In contrast, in the presence of vitronectin (Fig. 6A,
circles), there is saturable binding at much lower concentra-
tions. Evaluating the vitronectin-specific component of the
binding of PAI-1 by subtracting the contribution of PAI-1 bind-
ing to fibrin alone yields a sigmoidal binding isotherm (Fig. 6B)
that can be fit to the Hill equation with a Hill coefficient of 1.5
and maximal binding equal to 1 nM concentrations of PAI-1.
The Hill number is indicative of cooperativity between PAI-1-
binding sites on vitronectin. It is noteworthy that the binding
stoichiometry almost exactly equals 2 PAI-1 molecules per
vitronectin molecule. This result is consistent with our recent
report from biophysical analyses that indicates that higher
order complexes between vitronectin and PAI-1 are formed
with a molar binding ratio of 2:1 (PAI-1:vitronectin).2 Fig. 6C
shows a Scatchard analysis of the PAI-1 binding data that is
specific to vitronectin. The downward curvature of the plot at
low concentrations of bound ligand is indicative of cooperative
binding. The Scatchard plot is extremely sensitive to coopera-
tive binding and may be diagnostic in cases in which cooperat-
ivity is less apparent from the binding isotherms of the type
shown in Fig. 6B. This cooperative, bivalent binding of PAI-1 to
fibrin-associated vitronectin suggests that the initial binding of
one PAI-1 molecule induces conformational changes in fibrin-
bound vitronectin such that the second PAI-1-binding site on
vitronectin is more readily available for interacting with a
second PAI-1 molecule.
Although these results support the concept of two PAI-1-
binding sites, the cooperative nature of these binding interac-
tions make it virtually impossible to measure the dissociation
constants for each interaction using these experimental ap-
proaches. Furthermore, we cannot elucidate the mechanisms
regulating the binding preferences, or the communication be-
tween sites from these data alone. An estimate of the average
binding affinity, K0.5 in the Hill equation, using these data
gives a value of 1.5 nM, consistent with previously reported
high affinity measurements for PAI-1-vitronectin binding in-
teractions that were derived using an oversimplified 1:1 bind-
ing site model (25, 31, 33–37). Although not equivalent to a true
binding constant, this value of K0.5 reflects a high affinity
interaction that is in the range to give saturable binding of
approximately nanomolar concentrations of PAI-1 under the
conditions of this experiment, in which the vitronectin concen-
tration was fixed at 0.5 nM.
DISCUSSION
The studies presented in this report provide the first evi-
dence that vitronectin plays a critical role in the regulation of
PAI-1 binding to fibrin. Under a variety of experimental con-
ditions, we have demonstrated that fibrin-associated vitronec-
FIG. 5. Vitronectin-dependent stabilization of PAI-1 activity
on fibrin clots. Increasing doses of PAI-1 were incubated for 1 h at
37 °C in wells coated with fibrin (0.375 mM) formed in the presence
(circles) or absence (triangles) of vitronectin (0.5 nM), the unbound
PAI-1 was washed away, and samples were further incubated at 37 °C
for either 1 h (open symbols) or 24 h (closed symbols). After the specified
time points, the plasmin generation on the fibrin surface was monitored
by adding t-PA, plasminogen, and S-2251 to each well, and samples
were monitored every 1 min at 405 nm for 1 h. The rate of plasmin
generation was calculated for each condition, and data are plotted as
percentage of plasmin activity of control samples (no added PAI-1).
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tin influences fibrinolysis by serving as an intermolecular
bridge to support high affinity binding of PAI-1 to fibrin. In this
work, the importance of vitronectin as the mediator of fibrin-
associated PAI-1 activity is underscored by the finding that
PAI-1-mediated inhibition of clot lysis is vitronectin-dependent
in both purified fibrin and plasma clots. The concept that
vitronectin binds to fibrin and PAI-1 binds to fibrin via
vitronectin explains why both of these proteins have been im-
munolocalized on the surface of fibrin polymers (38, 39) and
provides a more plausible explanation for the mechanism by
which active PAI-1 binds to fibrin clots. Although our binding
studies confirm previous reports of a low affinity binding inter-
action of PAI-1 to fibrin, the physiological relevance of these
interactions is questionable. Given that plasma concentrations
of PAI-1 are in the nanomolar range, whereas the concentra-
tion of vitronectin is in the micromolar range, all active plasma
PAI-1 would be expected to be complexed with vitronectin.
Moreover, the observation that the reported low affinity fibrin-
binding site on PAI-1 overlaps with the vitronectin-binding
domain (16, 35, 40) implies that the fibrin-binding site on PAI-1
would be masked when PAI-1 is in complex with vitronectin.
A New Model for the PAI-1-dependent Inhibition of Fibrinol-
ysis—Our recent studies indicate that there are a limited num-
ber of specific vitronectin-binding sites available on fibrin.
Vitronectin binds saturably to these sites with an estimated
stoichiometry as high as 1 mol of vitronectin bound for every
20–70 mol of fibrin.3 When native vitronectin is in excess,
self-association of vitronectin on the fibrin surface is observed.
It is likely that this reflects cooperative binding interactions of
additional fluid-phase vitronectin subunits to the fibrin-bound
vitronectin multimers. In light of the high concentration of
vitronectin incorporated into purified or platelet-poor plasma
clots, it is not surprising that fibrin-associated vitronectin has
a major impact on PAI-1 binding to fibrin. For example, the
incorporation of 0.5 mM plasma vitronectin into clots may rep-
resent up to 1.0 mM PAI-1 binding capacity, an amount that is
significantly greater than the highest reported concentration of
plasma PAI-1 in any pathophysiological state.
Quantitative immunofluorescence confocal microscopy con-
firmed that .87% of the plasma PAI-1 colocalizes with
vitronectin aggregates along fibrin fibrils (Fig. 1). Moreover,
the functional importance of plasma vitronectin for PAI-1 in-
teractions with plasma clots was put to the test by examining
the effects of neutralizing antibodies directed against PAI-1
and vitronectin on the t-PA-mediated lysis. The 125I-fibrinogen-
labeled plasma clots were formed in the presence of 22 nM
PAI-1, a concentration of PAI-1 at the upper limit of its circu-
lating levels (Fig. 2). The monoclonal anti-PAI-1 IgG partially
attenuated the PAI-1 inhibitory effects on t-PA but did not
completely block its activity consistent with previous reports
with this antibody (11, 16). In contrast, affinity-purified anti-
vitronectin IgG completely blocked the PAI-1 effects on clot
lysis, raising the possibility that inhibiting the vitronectin-de-
pendent incorporation of PAI-1zvitronectin complexes into clots
may be a novel strategy to enhance in situ thrombolysis.
Fibrin-bound Vitronectin Mediates the Binding and Stabili-
zation of PAI-1 to Clots—The functional consequences of fibrin-
bound vitronectin on fibrin-bound PAI-1 activity was examined
with clots formed in the presence or absence of vitronectin and
then preincubated with PAI-1 for various times prior to meas-
uring t-PA-mediated plasmin generation on the fibrin surface
using an amidolytic assay (Fig. 5). The results confirmed the
presence of low affinity fibrin-binding sites for PAI-1 and dem-
onstrated that fibrin-bound vitronectin significantly increases
the level of stable fibrin-bound PAI-1 activity. In order to fur-
ther quantify the effects of vitronectin on PAI-1 binding to
fibrin, we incubated clots formed in the presence or absence of
vitronectin with increasing concentrations of 32P-HMK-PAI-1
(6 excess unlabeled PAI-1), and measured the specific radio-
activity that was bound (Fig. 6). The results confirm previous
reports of the presence of relatively low affinity binding sites
for PAI-1 on fibrin (15–18). Furthermore, these data indicate
that PAI-1 binds cooperatively to fibrin-bound vitronectin, with
a stoichiometry of 2 mol of PAI-1 bound per mol of fibrin-bound
vitronectin.
Some controversy has surfaced over the last few years re-
garding the issue of PAI-1-binding sites on vitronectin. Indeed,
PAI-1-binding sites have been localized to two distinct regions
of vitronectin. However, most of the binding data reported to
date for PAI-1 and vitronectin have been interpreted assuming
a single binding site model. This is despite the fact that early
binding experiments with one or the other reactant adsorbed to
FIG. 6. Dose-response of PAI-1 binding to fibrin formed in the presence or absence of vitronectin. Increasing doses of 32P-HMK-PAI-1
were incubated for 1 h at 37 °C in wells coated with fibrin (0.375 mM) formed in the absence or presence of vitronectin (0.5 nM). A shows total binding
to fibrin matrices formed in the presence (circles) or absence (squares) of vitronectin. The data in B, which represent binding to the fibrin matrix
that is strictly vitronectin-dependent, were generated by subtracting the amount of PAI-1 bound to fibrin alone from the amount of PAI-1 bound
to vitronectin-containing clots for the corresponding amounts of total PAI-1 added in the experiment. The fit to the data is a nonlinear fit to the
Hill equation, yielding a value for the Hill coefficient of 1.5 and a maximum amount of PAI-1 bound at saturating equal to 1 nM. The K0.5, or average
binding affinity for PAI-1 to fibrin-bound vitronectin, is approximately 1.5 nM from the fit. C shows a treatment of the data for PAI-1 binding that
is specific for fibrin-bound vitronectin using a Scatchard analysis. The downward curvature of the plot at lower concentrations of bound PAI-1 is
indicative of cooperative binding.
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a microtiter plate surface indicated ratios varying from 1:1
(vitronectin:PAI-1) with immobilized PAI-1 to a ratio of 1:3
(PAI-1:vitronectin) using immobilized vitronectin (32). The
PAI-1 binding studies in this study utilize vitronectin that is
co-localized with fibrin during coagulation, providing a surface
that likely displays vitronectin in a physiologically relevant
conformation. As noted above, this conformation of vitronectin
appears to bind two molecules of PAI-1. Our recent work using
analytical ultracentrifugation and monoclonal antibodies spe-
cific for different epitopes on vitronectin consistently provided
evidence for a 1:2 (vitronectin:PAI-1) stoichiometry of the com-
plex formed by the two proteins in solution.2 Taken together
with the results from this study on fibrin-associated vitronec-
tin, the data support the notion that both of the vitronectin
regions appear to be functional PAI-1-binding sites.
Our results support the concept that vitronectin is the me-
diator of PAI-1 binding to fibrin clots. Moreover, these results
confirm our previous report of a bivalent interaction between
PAI-1 and vitronectin2 and provide the first evidence that the
PAI-1zvitronectin complex is the physiological form that inter-
acts with fibrin. Many questions remaining regarding the
mechanism regulating PAI-1zvitronectin complex binding in-
teractions with fibrin remain. It is unlikely that Factor XIII
transglutaminase cross-linking of these proteins is involved,
because the binding of vitronectin to fibrin and the binding of
PAI-1 or PAI-1zvitronectin complexes to fibrin are independent
of cross-linking activity (not shown). These results are consist-
ent with the recent report that monocyte-derived PAI-2, but not
PAI-1, is cross-linked to fibrin (41). This difference implies that
these two inhibitors bind to thrombi through distinct mecha-
nisms. Clots formed in the presence of platelets also show
co-distribution of PAI-1zvitronectin complexes on fibrin (39).
These findings raise the possibility that the binding of platelet
PAI-1 to fibrin may also be vitronectin-dependent. Future stud-
ies will be aimed at further defining the mechanism regulating
fibrin interactions with vitronectin and with PAI-1zvitronectin
complexes and examining the role of fibrin-bound PAI-
1zvitronectin complexes in the organization of thrombi and in
angiogenesis.
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